Table 4.

Costs avoided with QIV versus TIV in the models populated with best available data inputs.

	FLOU	FLORA	FLORENCE 1-year	FLORENCE lifetime
Costs (R$) avoided (QIV vs TIV)
Vaccination costs	−145,682,900	−145,682,900	−145,682,900	−2,582,045,940
Vaccine price	−145,682,900	−145,682,900	−145,682,900	−2,581,917,946
Administration	0	0	0	−127,994
Disease management costs	6,116,403	7,143,967	9,663,447	197,280,934
Uncomplicated influenza treatment	745,089	1,025,150	3,395,349	63,263,085
NI treatment	NA	228,335	224,533	4,413,394
Antibiotics	NA	NA	2,325,639	45,740,323
Medical visits	745,089	796,815	845,177	13,109,368
Inpatient complication treatment	5,371,315	5,059,479	5,149,362	114,199,731
GP visit	NA	49,233	50,399	1,063,336
Hospitalizations	5,371,315	5,010,246	5,098,962	113,136,395
Outpatient complication treatment	NA	1,059,337	1,118,737	19,818,119
Total costs	−139,566,496	−138,538,933	−136,019,453	−2,384,765,005

Negative values = incremental costs, positive values = cost savings.

QIV vs TIV, quadrivalent versus trivalent influenza vaccine; NI, neuraminidase inhibitors; GP, general practitioner; NA, not applicable.